TABLE 3.

Estimates of pre to post and pre to follow-up between-group mean effect sizes for anxiety outcomes across brief EBIs.

	K	N	g	SDg	95% Cl		FSN	Qw
Pre to Post
Overall	64	10,384	0.19	0.27	0.11	0.27	287	189.60 (63)***
Treatment	25	1,300	0.35	0.36	0.20	0.50	80	24.65 (24)
Prevention	37	9,084	0.13	0.24	0.04	0.22	66	129.87 (38)***
Targeted Prevention	17	2,315	0.23	0.25	0.10	0.36	24	30.10 (16)*
Indicated Prevention	13	1,915	0.22	0.24	0.10	0.30	14	22.56 (12)*
Selective Prevention	4	400	0.31	0.27	0.06	0.46	2	7.22 (3)
Universal Prevention	17	6,769	0.09	0.19	−0.01	0.20	-	58.42 (16)***
Pre to Follow-up
Overall	30	6,440	0.24	0.24	0.13	0.34	80	91.94 (29)***
Treatment	6	235	0.30	0.50	0.04	0.56	4	13.74 (5)*
Prevention	23	5,855	0.22	0.23	0.12	0.33	43	77.45 (23)***
Targeted Prevention	15	2,057	0.29	0.28	0.14	0.44	24	17.94 (14)
Indicated Prevention	13	1,881	0.30	0.29	0.13	0.47	18	17.01 (12)
Selective Prevention	2	176	0.21	0.10	−0.09	0.51	-	0.004 (1)
Universal Prevention	8	3,798	0.17	0.17	0.03	0.32	4	26.70 (7)***

K = number of studies; N = sample size; g = weighted mean effect size; SDg = weighted standard deviation of g; 95% CI = 95% confidence interval; FSN = Fail-Safe N, which is the number of samples with an effect size of zero that should have been left out in order to reduce estimated effect size to non-significance; Q_w = Variability among effect sizes; Pre to follow-up is average of 8.88 months;

^*p <.05,

^**p <.01,

^***p <.001.